Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Animal Vaccines: 2nd Edition
share announcement

Animal Vaccines: 2nd Edition

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 6726

Special Issue Editors

Dr. Hsian-Yu Wang

E-Mail Website
Guest Editor
International Program in Animal Vaccine Technology, International College, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan
Interests: cell-culture-based vaccine manufacturing process; bioreactor; oral DNA vaccine vector; animal vaccine
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. David Benfield

E-Mail Website
Guest Editor
Department of Animal Sciences, The Ohio State University, Wooster Campus, 1680 Madison Avenue, Wooster, OH 44691, USA
Interests: virology, immunology and pathogenesis of diseases in large and companion animals; emerging viruses; RNA viruses; diagnostic virology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Scientists have attempted to use different kinds of novel technologies in animal vaccine development. Since the regulatory requirements of clinical trials for animal products are shorter than those in human vaccines, novel technologies are easier to commercialize in animal vaccine products. Many bacterial and eukaryotic cell-expressed recombinant proteins and viral vectors have been used for decades, and many kinds of immune potentiating materials, such as peptides, proteins, polymers, and emulsified oils, have been used in adjuvants. Biosafety and high immunization efficacy are the basic requirements of a vaccine. However, easily immunizing operations and low manufacturing costs are also essential for a successful animal vaccine product. This Special Issue will not only include novel antigen or adjuvant design but also cover large-scale production and manufacturing improvement technologies.

Dr. Hsian-Yu Wang
Prof. Dr. David Benfield
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal vaccines
  • novel antigen or adjuvant design
  • vaccine technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1468 KB  
Article
CHO Cell-Produced Truncated Bovine Ephemeral Fever Virus Glycoprotein as a Promising Subunit Vaccine Candidate for Cattle
by Huan-Yu Hsu, Shu-Ju Yeh, Chi-Chih Chen and Guan-Ming Ke
Vaccines 2026, 14(3), 265; https://doi.org/10.3390/vaccines14030265 - 15 Mar 2026
Viewed by 818
Abstract
Background/Objectives: Bovine ephemeral fever (BEF) is a significant disease affecting the cattle industry. The current control strategy for BEF in the field primarily relies on inactivated vaccines. However, some individuals have experienced hypersensitive reactions to these vaccines, prompting the exploration of subunit vaccines [...] Read more.
Background/Objectives: Bovine ephemeral fever (BEF) is a significant disease affecting the cattle industry. The current control strategy for BEF in the field primarily relies on inactivated vaccines. However, some individuals have experienced hypersensitive reactions to these vaccines, prompting the exploration of subunit vaccines as a potential alternative for BEF prevention. Glycoprotein (G protein)-based subunit vaccines derived from virions have successfully induced neutralizing antibodies in cattle for over a decade. Nevertheless, the lack of recent studies evaluating their efficacy using recombinant proteins has raised concerns regarding the development of BEF subunit vaccines for practical field application. Therefore, the objective of this study was to evaluate the antigenicity of a novel truncated G protein produced in mammalian cells as a candidate subunit vaccine for BEF in cattle. Methods: In this study, the G protein with full ectodomain and a version truncated at the C-terminal domain were successfully generated using the ExpiCHO™ expression system. Vaccine efficacy was evaluated weekly by measuring neutralizing antibody titers and cytokine mRNA expression levels following vaccination. Results: Results show that the recombinant protein s510, derived from the G protein of BEF, can stimulate cattle to produce an average 35-fold increase in neutralizing antibodies after three doses of vaccination. The significant upregulation of IFN-γ mRNA supports the effectiveness of the s510-based subunit vaccine and indicates the activation of a cytotoxic immune response in cattle following vaccination. Conclusions: In conclusion, the results indicate that the recombinant protein s510 is a promising antigen for future BEF subunit vaccine development in this study. Full article
(This article belongs to the Special Issue Animal Vaccines: 2nd Edition)
►▼ Show Figures

Graphical abstract

19 pages, 5486 KB  
Article
Establishment of Immune Biobank for Vaccine Immunogenicity Prediction Using In Vitro and In Silico Methods Against Porcine Reproductive and Respiratory Syndrome Virus
by Chaitawat Sirisereewan, John J. Byrne, Lanre Sulaiman, Abigail Williams, Ben M. Hause, Juliana Bonin Ferreira, Glen W. Almond, Benjamin Gabriel, Anne S. De Groot, Tobias Käser, Gustavo Machado and Elisa Crisci
Vaccines 2025, 13(10), 1052; https://doi.org/10.3390/vaccines13101052 - 14 Oct 2025
Cited by 1 | Viewed by 1768
Abstract
Background/Objectives: Porcine reproductive and respiratory syndrome virus (PRRSV) remains one of the most economically significant pathogens in the global swine industry. Despite the availability of commercial vaccines for over three decades, they fail to induce sterile immunity and often provide inconsistent protection against [...] Read more.
Background/Objectives: Porcine reproductive and respiratory syndrome virus (PRRSV) remains one of the most economically significant pathogens in the global swine industry. Despite the availability of commercial vaccines for over three decades, they fail to induce sterile immunity and often provide inconsistent protection against heterologous PRRSV strains. This study aimed to predict vaccine immunogenicity by detecting strain-specific immune responses that related to an immune correlate of protection (CoP) against different PRRSV-2 strains. Methods: Post-weaning pigs were vaccinated with five commercially available PRRSV-2 vaccines or received sterile PBS injection as a control. At 28 days post-vaccination (dpv), all pigs were humanely euthanized for large-volume blood collection to isolate peripheral blood mononuclear cells (PBMCs) and plasma, establishing the immune bank. PBMCs and plasma from each group were then tested against six PRRSV-2 strains to evaluate immune responses. In addition, T cell epitope coverage between vaccine and field PRRSV-2 strains was assessed using the EpiCC (in silico) tool to enhance predictive capacity. Results: While neutralizing antibodies were undetectable in all vaccinated pigs at 28 dpv, PRRSV-specific IFNγ–producing cells were detected at various levels in each vaccinated group following restimulation with different PRRSV-2 strains. Additionally, a positive correlation was observed for the EpiCC coverage of the N gene and mean IFNγ responses to VR2332 (SLA class I and II) and NC24-6 (SLA class II). Conclusions: The PRRSV immune bank demonstrated potential as a tool for predicting vaccine immunogenicity against different PRRSV-2 strains and EpiCC provides additional information on T cell epitope cross conservation. The combined approach may provide a valuable framework for selecting PRRSV vaccines for more effective prevention and control in endemic areas. Full article
(This article belongs to the Special Issue Animal Vaccines: 2nd Edition)
►▼ Show Figures

Figure 1

21 pages, 4108 KB  
Article
Respiratory Efficacy of a Multivalent Marker Vaccine Against Bovine Viral Diarrhoea Virus Types 1 and 2, Infectious Bovine Rhinotracheitis Virus, Bovine Respiratory Syncytial Virus, and Bovine Parainfluenza-3 Virus in Young Calves
by Carlos Montbrau, Marta Gibert, Marina Solé, Isabel Barril, Mercè Roca, Lucia Acal, Berta Vázquez, Joaquim Mallorqui and Ricard March
Vaccines 2025, 13(10), 999; https://doi.org/10.3390/vaccines13100999 - 24 Sep 2025
Cited by 2 | Viewed by 1916
Abstract
Background/Objectives: A new multivalent vaccine (DIVENCE® PENTA), containing Bovine viral diarrhoea virus (BVDV) types 1 and 2 recombinant proteins, live gE/tk double gene deleted Bovine Herpesvirus type 1 (BoHV-1 or IBR), live attenuated Bovine respiratory syncytial virus (BRSV) and inactivated parainfluenza-3 [...] Read more.
Background/Objectives: A new multivalent vaccine (DIVENCE® PENTA), containing Bovine viral diarrhoea virus (BVDV) types 1 and 2 recombinant proteins, live gE/tk double gene deleted Bovine Herpesvirus type 1 (BoHV-1 or IBR), live attenuated Bovine respiratory syncytial virus (BRSV) and inactivated parainfluenza-3 virus (PI-3) has been designed to protect cattle against the main viral pathogens associated with Bovine respiratory disease (BRD). The aim of this study was to demonstrate the efficacy of DIVENCE® PENTA against experimental infections with BVDV-1, BVDV-2, IBR, BRSV and PI-3 in young calves. Methods: Ten-week-old calves were given two intramuscular doses three weeks apart. The efficacy was evaluated by means of an experimental challenge three weeks after vaccination. Serology, clinical signs, rectal temperature, white blood cell count, viral shedding and lung lesions were monitored after the challenge. Results/Conclusions: The results demonstrated a significant sparing of BRD in calves vaccinated with DIVENCE® PENTA, as evidenced by fewer clinical signs, lower rectal temperatures, reduced viral shedding and less severe pulmonary lesions compared to control animals. A significant reduction in hyperthermia, leukopenia and viraemia post-challenge was also observed, highlighting the efficacy of the multivalent vaccine against BVDV types 1 and 2, IBR, BRSV and PI-3 in young calves. Full article
(This article belongs to the Special Issue Animal Vaccines: 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 843 KB  
Review
Potential of Bovine Herpesvirus Vectors for Recombinant Vaccines
by Eda Mert Gokduman, Mustafa Ozan Atasoy, Ayşe Gencay Goksu, İbrahim Sozdutmaz and Muhammad Munir
Vaccines 2026, 14(1), 6; https://doi.org/10.3390/vaccines14010006 - 20 Dec 2025
Viewed by 1338
Abstract
The livestock industry experiences significant economic losses as a result of viral infections. Building on recent advances in biotechnological research, recombinant viral vector vaccines have emerged as promising platforms for next-generation vaccines. These vaccines can overcome many limitations of conventional vaccines, as they [...] Read more.
The livestock industry experiences significant economic losses as a result of viral infections. Building on recent advances in biotechnological research, recombinant viral vector vaccines have emerged as promising platforms for next-generation vaccines. These vaccines can overcome many limitations of conventional vaccines, as they provide stronger protective immune profiles, stability, and improved safety profiles for various diseases. Bovine herpesviruses serve as viral vector platforms utilized due to their large genome capacity, potential for multigenic antigen delivery, and significant immune stimulation. In this review, we explored the structural characteristics and genomic organization of bovine alphaherpesviruses (BoHV-1, BoHV-4, and BoHV-5), covered BoHV-5 biology and attenuation strategies as part of the comparative platform analysis, and summarised the latest advancements in molecular tools used for viral genome editing. We further highlight the development of vaccines against bovine and zoonotic pathogens, discuss applications of BoHV-based vectors, and deliberate on future directions to improve vaccine efficacy. It also discussed the current state of research in the field, considered prospects, and outlined strategies for impending research. BoHV vectors are promising candidates as next-generation vaccine platforms in veterinary medicine and will play an important role in integrated disease control in livestock. Full article
(This article belongs to the Special Issue Animal Vaccines: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop